Zhu et al. conducted a study on PDAC and reported that genetic or pharmacologic inhibition of the HSPA5-GPX4 pathway enhanced gemcitabine sensitivity by disinhibiting ferroptosis in vitro and subcutaneously and orthotopically, which hinted that HSPA5 may be a potential target against pancreatic cancer [42]. Here, HSPA5 is linked to familial pancreatic carcinoma.